Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

The role of calendars may be growing more important when managing patients with nAMD and DME. How many weeks can patients go between injections with newer anti-VEGF agents versus older options? How short of an injection interval can patients tolerate before it becomes too much of a burden?

In this podcast, Murtaza Adam, MD; Laxmi Devisetty, MD, Hong-Uyen Hua, MD; and Sherrol Reynolds, OD; share insights into determining appropriate treatment regimens with these therapies and supporting patient adherence.

Faculty Credentials:

Murtaza Adam, MD

Partner Physician

Chair, Clinical Research Committee

Colorado Retina Associates

Adjunct Clinical Associate Professor

Rocky Vista University

Denver, CO

Laxmi V. Devisetty, MD

Ophthalmologist

Retina Specialist

Vitreoretinal Surgeon

NJRetina

Union, New Jersey

Hong-Uyen Hua, MD

Assistant Professor of Clinical Ophthalmology

Pediatric and Adult Retina Specialist

Bascom Palmer Eye Institute

University of Miami Health System

Miami, FL

Sherrol A. Reynolds, OD

Professor of Optometry

College of Optometry

Nova Southeastern University

Chief, Advanced Ophthalmic Care and Specialty Testing

The Eye Care Institute

Fort Lauderdale, FL